Table 4.
Immunohistochemical analyses of relevant markers for Breast Cancer (2000–2015)
| Total n = 3451 |
Luminal A n = 863 |
Luminal B n = 122 |
HER-2+ n = 76 |
Triple Neg n = 193 |
Unclassified n = 2197 |
Statistical test | |
|---|---|---|---|---|---|---|---|
| P53 | < 0.001b | ||||||
| Negative | 363 (27.7%) | 131 (16.9%) | 38 (35.2%) | 42 (61.8%) | 93 (52.8%) | 59 (31.9%) | |
| Positive | 947 (72.2%) | 643 (83.1%) | 70 (64.8%) | 26 (38.2%) | 83 (47.2%) | 125 (67.6%) | |
| Borderline | 1 (0.0%) | – | – | – | – | 1 (0.5%) | |
| Missing | 2140 | 89 | 14 | 8 | 17 | 2012 | |
| Cytokeratin 5/6 | < 0.01a | ||||||
| Negative | 215 (76.5%) | 101 (70.6%) | 32 (94.1%) | 7 (77.8%) | 25 (92.6%) | 50 (73.5%) | |
| Positive | 66 (23.5%) | 42 (29.4%) | 2 (5.9%) | 2 (22.2%) | 2 (7.4%) | 18 (26.5%) | |
| Missing | 3170 | 720 | 88 | 67 | 166 | 2129 | |
| Ki67 | < 0.001b | ||||||
| Negative | 512 (52.1%) | 222 (39.6%) | 40 (60.6%) | 37 (69.8%) | 103 (76.3%) | 110 (65.5%) | |
| Positive | 459 (46.7%) | 335 (59.7%) | 26 (39.4%) | 15 (28.3%) | 28 (20.7%) | 55 (32.7%) | |
| Borderline | 12 (1.2%) | 4 (0.7%) | – | 1 (1.9%) | 4 (3.0%) | 3 (1.8%) | |
| Missing | 2468 | 302 | 56 | 23 | 58 | 2029 |
aSignificance obtained from ANOVA test statistic bSignificance obtained from Chi-Square test statistic